Markov model of smoking cessation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue SUPPL. 3, 2011, Pages 15549-15556

  Killeen, Peter R ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Monoamine oxidase; Nicotine; Quitting tobacco; Survival model

Indexed keywords

NICOTINE PATCH;

CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE COMPARISON; HIDDEN MARKOV MODEL; HUMAN; PRIORITY JOURNAL; RELAPSE; SMOKING; SMOKING CESSATION; SURVIVAL;

NICOTIANA TABACUM;

EID: 80053147819     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1011277108     Document Type: Article

References (109)

1. Centers for Disease Control and Prevention (2002) From the Centers for Disease Control and Prevention. Annual smoking attributable mortality, years of potential life lost and economic costs-United States, 1995-1999. JAMA 287:2355-2356.
2. Stead LF, Perera R, Bullen C, Mant D, Lancaster T (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 1:CD000146.
3. Piasecki TM, Fiore MC, McCarthy DE, Baker TB (2002) Have we lost our way? The need for dynamic formulations of smoking relapse proneness. Addiction 97: 1093-1108.
4. Salber EJ, Abelin T (1967) Smoking behavior of Newton school children - 5-year follow-up. Pediatrics 40:363-372.
5. DiFranza JR, et al. (2007) Symptoms of tobacco dependence after brief intermittent use: The Development and Assessment of Nicotine Dependence in Youth-2 study. Arch Pediatr Adolesc Med 161:704-710. (Pubitemid 47026331)
6. Westman EC, Behm FM, Simel DL, Rose JE (1997) Smoking behavior on the first day of a quit attempt predicts long-term abstinence. Arch Intern Med 157:335-340. (Pubitemid 27066404)
7. al'Absi M, Hatsukami D, Davis GL, Wittmers LE (2004) Prospective examination of effects of smoking abstinence on cortisol and withdrawal symptoms as predictors of early smoking relapse. Drug Alcohol Depend 73:267-278. (Pubitemid 38231038)
8. Zhu SH, et al. (1996) Telephone counseling for smoking cessation: Effects of singlesession and multiple-session interventions. J Consult Clin Psychol 64:202-211.
9. Gilpin E, Pierce JP (1994) Measuring smoking cessation: Problems with recall in the 1990 California Tobacco Survey. Cancer Epidemiol Biomarkers Prev 3:613-617. (Pubitemid 24314451)
10. Nides MA, et al. (1995) Predictors of initial smoking cessation and relapse through the first 2 years of the Lung Health Study. J Consult Clin Psychol 63:60-69.
11. ChornockWM, Stitzer ML, Gross J, Leischow S (1992) Experimental model of smoking re-exposure: Effects on relapse. Psychopharmacology (Berl) 108:495-500.
12. Borland R (1990) Slip-ups and relapse in attempts to quit smoking. Addict Behav 15: 235-245.
13. Brandon TH, Tiffany ST, Obremski KM, Baker TB (1990) Postcessation cigarette use: The process of relapse. Addict Behav 15:105-114. (Pubitemid 20155202)
14. Hughes JR, et al. (2003) Measures of abstinence in clinical trials: Issues and recommendations. Nicotine Tob Res 5:13-25. (Pubitemid 36285465)
15. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: A practical guide. Med Decis Making 13:322-338. (Pubitemid 24013155)
16. Frenk H, Dar R (2000) A Critique of Nicotine Addiction (Kluwer, Boston).
17. Heyman GM (2009) Addiction: A Disorder of Choice (Harvard University Press, Cambridge, MA).
18. Littrell J (2010) Perspectives emerging from neuroscience on how people become addicted and what to do about it. J Soc Work Pract Addict 10:229-256.
19. Fowler JS, et al. (2010) Reversible inhibitors of monoamine oxidase-A (RIMAs): Robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology 35:623-631.
20. Ross SR (1997) Introduction to Probability Models (Academic, San Diego), 6th Ed.
21. Juliano LM, Donny EC, Houtsmuller EJ, Stitzer ML (2006) Experimental evidence for a causal relationship between smoking lapse and relapse. J Abnorm Psychol 115: 166-173.
22. Hughes JR (2010) Craving among long-abstinent smokers: An Internet survey. Nicotine Tob Res 12:459-462.
23. Lancaster T, Hajek P, Stead LF, West R, Jarvis MJ (2006) Prevention of relapse after quitting smoking: A systematic review of trials. Arch Intern Med 166:828-835.
24. Hughes JR, Peters EN, Naud S (2008) Relapse to smoking after 1 year of abstinence: A meta-analysis. Addict Behav 33:1516-1520.
25. Peters EN, Hughes JR (2009) The day-to-day process of stopping or reducing smoking: A prospective study of self-changers. Nicotine Tob Res 11:1083-1092.
26. Giovino GA (2002) Epidemiology of tobacco use in the United States. Oncogene 21: 7326-7340.
27. West R, Sohal T (2006) "Catastrophic" pathways to smoking cessation: Findings from national survey. BMJ 332:458-460. (Pubitemid 43342044)
28. Hughes JR, Callas PW (2010) Data to assess the generalizability of samples from studies of adult smokers. Nicotine Tob Res 12:73-76.
29. Shiffman S, Di Marino ME, Sweeney CT (2005) Characteristics of selectors of nicotine replacement therapy. Tob Control 14:346-355. (Pubitemid 41396483)
30. Hughes JR, Keely J, Naud S (2004) Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 99:29-38. (Pubitemid 38142221)
31. Silagy C, Lancaster T, Stead L, Mant D, Fowler G (2003) Nicotine replacement therapy for smoking cessation (Cochrane Review). The Cochrane Library (John Wiley & Sons, Chichester, UK), Issue 4. Available at http://personales.unican.es/ayestaf/esh/Nicotine %20replacement%20therapy%20for%20smoking%20cessation.htm.
32. Burnham KP, Anderson DR (2002) Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach (Springer, New York), 2nd Ed.
33. Killen JD, Fortmann SP, Davis L, Varady A (1997) Nicotine patch and self-help video for cigarette smoking cessation. J Consult Clin Psychol 65:663-672. (Pubitemid 27343837)
34. Hughes JR (2007) Effects of abstinence from tobacco: Etiology, animal models, epidemiology, and significance. A subjective review. Nicotine Tob Res 9:329-339.
35. Stapleton JA, et al. (1995) Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 90:31-42.
36. Richmond RL, Kehoe L (2007) Ten-year survival outcome of the nicotine transdermal patch with cognitive behavioural therapy. Aust N Z J Public Health 31:282-285. (Pubitemid 47072353)
37. Jamerson BD, et al. (2001) Late-term smoking cessation despite initial failure: An evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo. Clin Ther 23:744-752. (Pubitemid 32472605)
38. Nordstrom BL, et al. (2000) Predictors of continued smoking over 25 years of followup in the normative aging study. Am J Public Health 90:404-406. (Pubitemid 30115416)
39. Blöndal T, Franzon M, Westin A (1997) A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. Eur Respir J 10:1585-1590. (Pubitemid 27311077)
40. Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A (1999) Nicotine nasal spray with nicotine patch for smoking cessation: Randomised trial with six year follow up. BMJ 318:285-288.
41. Harrell FE (2001) Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis (Springer, New York).
42. Swan GE, Ward MM, Jack LM, Javitz HS (1993) Cardiovascular reactivity as a predictor of relapse in male and female smokers. Health Psychol 12:451-458.
43. Bland JM, Altman DG (1998) Survival probabilities (the Kaplan-Meier method). BMJ 317:1572-1580.
44. Satagopan JM, et al. (2004) A note on competing risks in survival data analysis. Br J Cancer 91:1229-1235. (Pubitemid 39424779)
45. Shiffman S, West RJ, Gilbert DG; SRNT Work Group on the Assessment of Craving and Withdrawal in Clinical Trials (2004) Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res 6: 599-614. (Pubitemid 39248146)
46. Shiffman S, et al. (2006) Analyzing milestones in smoking cessation: Illustration in a nicotine patch trial in adult smokers. J Consult Clin Psychol 74:276-285. (Pubitemid 43807360)
47. Stapleton JA, Sutherland G, Russell MAH (1998) How much does relapse after one year erode effectiveness of smoking cessation treatments? Long-term follow up of randomised trial of nicotine nasal spray. BMJ 316:830-831. (Pubitemid 28112430)
48. Krall EA, Garvey AJ, Garcia RI (2002) Smoking relapse after 2 years of abstinence: Findings from the VA Normative Aging Study. Nicotine Tob Res 4:95-100. (Pubitemid 34521101)
49. Hughes JR, Carpenter MJ, Naud S (2010) Do point prevalence and prolonged abstinence measures produce similar results in smoking cessation studies? A systematic review. Nicotine Tob Res 12:756-762.
50. Schneider NG, et al. (1995) Efficacy of a nicotine nasal spray in smoking cessation: A placebo-controlled, double-blind trial. Addiction 90:1671-1682.
51. Cummings SR, Richard RJ (1988) Optimum cutoff points for biochemical validation of smoking status. Am J Public Health 78:574-575.
52. Schneider NG, et al. (1996) Efficacy of a nicotine inhaler in smoking cessation: A double-blind, placebo-controlled trial. Addiction 91:1293-1306. (Pubitemid 26315887)
53. Lindsey JC, Ryan LM (1998) Tutorial in biostatistics methods for interval-censored data. Stat Med 17:219-238. (Pubitemid 28043593)
54. Tønnesen P, et al. (1999) Higher dosage nicotine patches increase one-year smoking cessation rates: Results from the European CEASE trial. Eur Respir J 13:238-246. (Pubitemid 29086814)
55. Kirshenbaum AP, Olsen DM, Bickel WK (2009) A quantitative review of the ubiquitous relapse curve. J Subst Abuse Treat 36:8-17.
56. Wennike P, Danielsson T, Landfeldt B, Westin A, Tønnesen P (2003) Smoking reduction promotes smoking cessation: Results from a double blind, randomized, placebocontrolled trial of nicotine gum with 2-year follow-up. Addiction 98:1395-1402. (Pubitemid 37297246)
57. Hatziandreu EJ, et al. (1990) Quitting smoking in the United States in 1986. J Natl Cancer Inst 82:1402-1406. (Pubitemid 20261053)
58. Roethig HJ, et al. (2009) Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. Nicotine Tob Res 11:1216-1225.
59. Hughes JR (2006) Clinical significance of tobacco withdrawal. Nicotine Tob Res 8: 153-156.
60. Hughes JR (2007) Effects of abstinence from tobacco: Valid symptoms and time course. Nicotine Tob Res 9:315-327.
61. Bevins RA, Caggiula AR (2009) The Motivational Impact of Nicotine and Its Role in Tobacco Use (Springer, New York).
62. Windom RE (1988) The health consequences of smoking: Nicotine addiction. 20th Report of the Surgeon General (Surgeon General, Superintendent of Documents, Washington, DC).
63. Donny EC, et al. (2003) Operant responding for a visual reinforcer in rats is enhanced by noncontingent nicotine: Implications for nicotine self-administration and reinforcement. Psychopharmacology (Berl) 169:68-76. (Pubitemid 37088616)
64. Palmatier MI, et al. (2007) The reinforcement enhancing effects of nicotine depend on the incentive value of non-drug reinforcers and increase with repeated drug injections. Drug Alcohol Depend 89:52-59. (Pubitemid 46604860)
65. Thiel KJ, Sanabria F, Neisewander JL (2009) Synergistic interaction between nicotine and social rewards in adolescent male rats. Psychopharmacology (Berl) 204:391-402.
66. Rose JE (1996) Nicotine addiction and treatment. Annu Rev Med 47:493-507.
67. Mansvelder HD, McGehee DS (2002) Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 53:606-617. (Pubitemid 35375590)
68. Markou A (2008) Review. Neurobiology of nicotine dependence. Philos Trans R Soc Lond B Biol Sci 363:3159-3168.
69. Bała MM, Leśniak W, Strzeszyński Ł (2008) Efficacy of pharmacological methods used for treating tobacco dependence: Meta-analysis. Pol Arch Med Wewn 118:20-28.
70. Wu P, Wilson K, Dimoulas P, Mills EJ (2006) Effectiveness of smoking cessation therapies: A systematic review and meta-analysis. BMC Public Health 6:300.
71. Dar R, Frenk H (2004) Do smokers self-administer pure nicotine? A review of the evidence. Psychopharmacology (Berl) 173:18-26. (Pubitemid 38591142)
72. West R, et al. (2000) A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl) 149:198-202. (Pubitemid 30262332)
73. Talhout R, Opperhuizen A, Van Amsterdam JGC (2007) Role of acetaldehyde in tobacco smoke addiction. Eur Neuropsychopharmacol 17:627-636. (Pubitemid 47268752)
74. Rose JE (2006) Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl) 184:274-285.
75. Herraiz T, Chaparro C (2005) Human monoamine oxidase is inhibited by tobacco smoke: β-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun 326:378-386. (Pubitemid 39593558)
76. Fowler JS, et al. (1996) Inhibition of monoamine oxidase B in the brains of smokers. Nature 379:733-736. (Pubitemid 26061736)
77. Fowler JS, Logan J, Wang GJ, Volkow ND (2003) Monoamine oxidase and cigarette smoking. Neurotoxicology 24:75-82. (Pubitemid 36091163)
78. Youdim MBH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295-309.
79. Belluzzi JD, Wang R, Leslie FM (2005) Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology 30:705-712. (Pubitemid 40397076)
80. Guillem K, et al. (2005) Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J Neurosci 25:8593-8600. (Pubitemid 41362035)
81. Villégier AS, Blanc G, Glowinski J, Tassin JP (2003) Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors. Pharmacol Biochem Behav 76:267-274. (Pubitemid 37329847)
82. Hauser RA, Holford NHG (2002) Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 17:961-968. (Pubitemid 36041001)
83. Lanteri C, et al. (2009) Inhibition of monoamine oxidases desensitizes 5-HT1A autoreceptors and allows nicotine to induce a neurochemical and behavioral sensitization. J Neurosci 29:987-997.
84. Lewis A, Miller JH, Lea RA (2007) Monoamine oxidase and tobacco dependence. Neurotoxicology 28:182-195. (Pubitemid 46187252)
85. George TP, Weinberger AH (2008) Monoamine oxidase inhibition for tobacco pharmacotherapy. Clin Pharmacol Ther 83:619-621. (Pubitemid 351417061)
86. Berlin I (2007) Monoamine oxidase inhibitors for smoking cessation. Medication Treatments for Nicotine Dependence, ed George TP (CRC, Boca Raton, FL), pp 109-120.
87. Guillem K, Vouillac C, Koob GF, Cador M, Stinus L (2008) Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal-induced place aversion. Biol Psychiatry 63:158-163. (Pubitemid 350299328)
88. Norman AB, Battaglia G, Creese I (1987) Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: A key to receptor regulatory mechanisms. J Neurosci 7: 1484-1491. (Pubitemid 17116100)
89. Fehr C, et al. (2008) Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry 165:507-514. (Pubitemid 351694294)
90. Henningfield JE, et al. (2004) Reducing tobacco addiction through tobacco product regulation. Tob Control 13:132-135. (Pubitemid 39452013)
91. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F (2009) Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 56 (Suppl 1):3-8.
92. Johnson PM, Kenny PJ (2010) Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci 13:635-641.
93. Koob GF (2009) Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 56 (Suppl 1):18-31.
94. Van Amsterdam J, Talhout R, Vleeming W, Opperhuizen A (2006) Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction. Life Sci 79: 1969-1973. (Pubitemid 44528577)
95. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F (2007) Dopamine in drug abuse and addiction: Results of imaging studies and treatment implications. Arch Neurol 64:1575-1579. (Pubitemid 350106758)
96. Huang SY, et al. (2007) Monoamine oxidase-A polymorphisms might modify the association between the dopamine D2 receptor gene and alcohol dependence. J Psychiatry Neurosci 32:185-192.
97. Ashby FG, O'Brien JB (2008) The Prep statistic as a measure of confidence in model fitting. Psychon Bull Rev 15:16-27.
98. Miller R, et al. (2005) How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 32:185-197. (Pubitemid 41712739)
99. Bullen C, et al. (2010) Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: Randomised cross-over trial. Tob Control 19:98-103.
100. Furberg H, et al. (2005) Is Swedish snus associated with smoking initiation or smoking cessation? Tob Control 14:422-424. (Pubitemid 41759618)
101. Gartner CE, et al. (2007) Assessment of Swedish snus for tobacco harm reduction: An epidemiological modelling study. Lancet 369:2010-2014. (Pubitemid 46899160)
102. Caldwell B, Burgess C, Crane J (2010) Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers. Nicotine Tob Res 12:179-183.
103. Herraiz T, Chaparro C (2006) Human monoamine oxidase enzyme inhibition by coffee and β-carbolines norharman and harman isolated from coffee. Life Sci 78:795-802. (Pubitemid 43082301)
104. Garvey AJ, Bliss RE, Hitchcock JL, Heinold JW, Rosner B (1992) Predictors of smoking relapse among self-quitters: A report from the Normative Aging Study. Addict Behav 17:367-377.
105. Doherty K, Kinnunen T, Militello FS, Garvey AJ (1995) Urges to smoke during the first month of abstinence: Relationship to relapse and predictors. Psychopharmacology (Berl) 119:171-178.
106. Gilbert DG, et al. (2002) Mood disturbance fails to resolve across 31 days of cigarette abstinence in women. J Consult Clin Psychol 70:142-152. (Pubitemid 34150981)
107. Hughes JR (1992) Tobacco withdrawal in self-quitters. J Consult Clin Psychol 60:689-697.
108. Hurt RD, et al. (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195-1202. (Pubitemid 27454451)
109. Ward MM, Swan GE, Jack LM (2001) Self-reported abstinence effects in the first month after smoking cessation. Addict Behav 26:311-327. (Pubitemid 32409917)